AI assistant
Sending…
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021
Aug 16, 2021
29977_dirs_2021-08-16_d028c72c-2dec-4379-bafd-075788f39c14.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-08-13
Reporting Person: COLES N ANTHONY (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-13 | Common Stock | M | 2000 | $345.47 | Acquired | 2902 | Direct |
| 2021-08-13 | Common Stock | S | 2000 | $625.0 | Disposed | 902 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-13 | Non-Qualified Stock Option (right to buy) | $345.47 | M | 2000 | Disposed | 2027-01-27 | Common Stock (2000) | Direct |
Footnotes
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
More from REGENERON PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 8
Major Shareholding Notification
2026
Apr 30
Interim / Quarterly Report
2026
Apr 29
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Regulatory Filings
2026
Apr 8
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3